Myeloma Clinical Trials
As one of the nation’s leading academic medical centers, UT Southwestern Medical Center offers a broad spectrum of clinical trials aimed at improving the outcomes of patients with myeloma.
Clinical trials are a type of research that is critical in developing new therapies for myeloma. Clinical trials often give patients access to leading-edge treatments that are not yet widely available.
Patients who qualify and choose to participate in a clinical trial at Harold C. Simmons Comprehensive Cancer Center might receive treatments years before they are available to the public. Patients interested in participating in a clinical trial should speak with their doctor.
Two of our current myeloma clinical trials are:
- Study Comparing Daratumumab, Lenalidomide,
Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and
Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma
- NCI-MATCH: Targeted Therapy Directed by Genetic Testing in
Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple